Beijing Chunlizhengda Medical Instruments Co., Ltd. (abbrev. Chunli Medical) has filed its Monthly Return for Equity Issuer covering the period ended 30 September 2026, confirming a stable share base across both its Hong Kong-listed H shares and Shanghai-listed A shares.

Chunli Medical’s authorised and registered share capital remained unchanged at 383.57 million shares, each with a par value of RMB 1.00. The structure continues to comprise 95.14 million H shares listed in Hong Kong and 288.43 million A shares listed on the Shanghai Stock Exchange.

Issued H shares totaled 95.14 million, with no treasury shares outstanding and no movement during the month. The company affirmed compliance with the Hong Kong Stock Exchange’s public-float requirement, meeting the 5 percent minimum threshold applicable to PRC issuers.

On the Shanghai market, issued A shares stood at 288.43 million, of which 1.38 million are held as treasury shares, leaving 287.05 million shares in public hands. There were no changes to the A-share count or treasury position over the reporting period.

The filing notes that the company had no share options, warrants, convertible securities, or other equity-linked instruments outstanding, nor were there any new issuances, cancellations, or repurchases in September.

Directors confirmed that all statutory and regulatory obligations related to the company’s share capital continue to be met. Overall, the September 2026 return underscores a month of capital stability for Chunli Medical, with its share structure and public-float levels intact.